| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
National Cancer Institute National Institutes of Health Bethesda, Maryland 20014
Data are reported on 1, 255 synthetic compounds which were tested in the CCNSC primary screens. Almost all of the compounds were tested in Sarcoma 180, Carcinoma 755, Leukemia 1210, and KB cells in culture; some tests were also carried out in Dunning leukemia ascites, Friend virus leukemia, Lewis lung carcinoma, Human sarcoma HS1, Hepatoma 129, Walker 256 (intramuscular) and Cloudman melanoma (S91). Data are reported only on compounds which have not demonstrated sufficient activity in these systems to warrant further investigation.
1 Former Chief, Cancer Chemotherapy National Service Center.
2 Biologist, Screening Section, Drug Evaluation Branch, Cancer Chemotherapy National Service Center.
3 Chief, Cancer Chemotherapy National Service Center.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |